Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients

被引：17
|
作者：
Kotton, Camille N. [1 ]
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St,Cox 5, Boston, MA 02114 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2022年 / 175卷 / 06期
关键词：
D O I：
10.7326/M22-1026
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：892 / +
页数：4
相关论文
共 50 条
  • [21] Tixagevimab-cilgavimab for preventing breakthrough COVID-19 in dialysis patients: a prospective study
    Boongird, Sarinya
    Srithongkul, Thatsaphan
    Sethakarun, Sethanant
    Bruminhent, Jackrapong
    Kiertiburanakul, Sasisopin
    Nongnuch, Arkom
    Kitiyakara, Chagriya
    Sritippayawan, Suchai
    CLINICAL KIDNEY JOURNAL, 2024, 17 (11)
  • [22] Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
    Podgorski, Christopher
    Parks, Deborah
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4548 - 4549
  • [23] Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19
    Abramowicz, Mark
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (04): : 384 - 385
  • [24] Observational study of COVID-19 prophylactic antibody (tixagevimab/cilgavimab) administration for multiple myeloma patients
    Lee, Yoojin
    Jo, Jae-Cheol
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S298 - S298
  • [25] Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients With Systemic Autoimmune Rheumatic Diseases
    Kawano, Yumeko
    Wang, Xiaosong
    Patel, Naomi J.
    Qian, Grace
    Kowalski, Emily
    Bade, Katarina J.
    Vanni, Kathleen M. M.
    Jonsson, A. Helena
    Williams, Zachary K.
    Cook, Claire E.
    Srivatsan, Shruthi
    Wallace, Zachary S.
    Sparks, Jeffrey A.
    JOURNAL OF RHEUMATOLOGY, 2024, 51 (03) : 305 - 312
  • [26] Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases
    Thomas, Marion
    Masson, Maeva
    Bitoun, Samuel
    Hamroun, Sabrina
    Seror, Raphaele
    Dupuy, Henry
    Lazaro, Estibaliz
    Richez, Christophe
    Allanore, Yannick
    Avouac, Jerome
    RHEUMATOLOGY, 2024, 63 (06) : 1632 - 1638
  • [27] Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in Kidney Transplant Recipients
    Benotmane, Ilies
    Olagne, Jerome
    Gautier-Vargas, Gabriela
    Cognard, Noelle
    Heibel, Francoise
    Braun-Parvez, Laura
    Keller, Nicolas
    Martzloff, Jonas
    Perrin, Peggy
    Pszczolinski, Romain
    Moulin, Bruno
    Fafi-Kremer, Samira
    Caillard, Sophie
    TRANSPLANTATION, 2023, 107 (08) : E215 - E218
  • [28] Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies
    Patrick Reimann
    Verena Petzer
    Axel Mündlein
    Bernd Hartmann
    Luciano Severgnini
    Alex Winkler
    Theresia Lang
    Minh Huynh
    Klaus Gasser
    Julia Rüger
    Michele Atzl
    Sylvia Mink
    Peter Fraunberger
    Stefan Schmidt
    Normann Steiner
    Andrea Griesmacher
    Eberhard Gunsilius
    David Nachbaur
    Wolfgang Willenbacher
    Dominik Wolf
    Thomas Winder
    Magdalena Anna Benda
    Annals of Hematology, 2024, 103 : 2123 - 2131
  • [29] Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
    Gidari, Anna
    Sabbatini, Samuele
    Bastianelli, Sabrina
    Pierucci, Sara
    Busti, Chiara
    Svizzeretto, Elisabetta
    Tommasi, Andrea
    Pallotto, Carlo
    Schiaroli, Elisabetta
    Francisci, Daniela
    VIRUSES-BASEL, 2024, 16 (03):
  • [30] Prophylactic effect of tixagevimab–cilgavimab on COVID-19 infection and death in Japanese patients with B cell lymphoma
    Hiro Tatetsu
    Yusuke Higuchi
    Takafumi Shichijo
    Kazutaka Oda
    Hirotomo Nakata
    Jun-ichirou Yasunaga
    Kisato Nosaka
    Masao Matsuoka
    International Journal of Hematology, 2023, 118 : 303 - 305
12345